Rotkreuzklinikum Muenchen gGmbH

At Rotkreuzklinikum Muenchen gGmbH, most trials focus on neoplasms, especially a wide range of breast cancer subtypes. Research includes HER2-positive, HER2-negative, hormone receptor-positive, and triple-negative breast cancer, with studies designed to test new treatment options, improve recurrence prevention, and better control advanced disease.

• Testing newer therapies for early and advanced breast cancer
• Improving outcomes in HER2-positive and HR-positive disease
• Evaluating approaches for triple-negative breast cancer and high-risk recurrence settings
• Supporting more effective treatment selection after surgery or in metastatic disease

This work reflects a strong focus on personalized oncology, with many studies exploring ways to extend disease control and reduce the chance of relapse.

The site also conducts research in hemic and lymphatic diseases, including acute myeloid leukemia, multiple myeloma, and several forms of lymphoma. These trials aim to improve treatment effectiveness, deepen remission, and support better disease control in both newly diagnosed and relapsed settings.

• Evaluating new combinations for acute myeloid leukemia
• Studying treatment strategies in multiple myeloma, including relapsed and newly diagnosed cases
• Assessing therapies for aggressive and relapsed lymphoma
• Exploring better response and durability of benefit in blood cancers

These studies show a clear interest in advancing care for complex hematologic cancers, where treatment choice can strongly influence long-term outcomes.

In addition to breast and blood cancers, the clinical research portfolio includes ovarian cancer, endometrial cancer, and germ cell tumors. The trials are aimed at testing new therapies, comparing treatment strategies, and improving survival in cancers that are often difficult to treat once advanced or recurrent.

• Investigating new options for ovarian cancer, including platinum-resistant disease
• Studying targeted approaches in endometrial cancer
• Comparing treatment strategies for germ cell tumors and seminoma
• Seeking better control of recurrent or metastatic gynecologic cancers

The Gynaecology department at this hospital contributes to research that combines treatment innovation with practical efforts to improve outcomes for patients facing advanced disease.